Nexavar (sorafenib) is a small molecule pharmaceutical. Sorafenib was first approved as Nexavar on 2005-12-20. It is used to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms in the USA. It has been approved in Europe to treat hepatocellular carcinoma and renal cell carcinoma. The pharmaceutical is active against mast/stem cell growth factor receptor Kit, receptor-type tyrosine-protein kinase FLT3, and vascular endothelial growth factor receptor 2. In addition, it is known to target serine/threonine-protein kinase B-raf, platelet-derived growth factor receptor beta, cyclin-dependent kinase 19, proto-oncogene tyrosine-protein kinase receptor Ret, vascular endothelial growth factor receptor 3, discoidin domain-containing receptor 2, fibroblast growth factor receptor 1, RAF proto-oncogene serine/threonine-protein kinase, and cyclin-dependent kinase 8. Nexavar's patents are valid until 2028-09-10 (FDA).
|Indication||hepatocellular carcinoma, renal cell carcinoma, thyroid neoplasms|
|Drug Class||Raf kinase inhibitors|